[Aggressive transformation and extramedullary tumor formation in IgA-lambda multiple myeloma].
A 52-year-old woman complained of lower back pain and gluteal pain in April 1997, and was found to have anemia, hypercalcemia and renal disorder. In September of the same year, she was diagnosed as having IgA-lambda myeloma (stage IIIA). VMMD-IFN therapy was started in November, 1997, and this resulted in improvement of the M-protein level, and relief of the pain in the lower back and gluteal region. A second course of VMMD-IFN therapy was also effective. In April 1998, however, the back pain worsened, and in July the patient suffered a fall and fractured her left femur. Upon readmission to our hospital, the level of M-protein was lower, and high fever, hypercalcemia, renal disorder, elevation of the LDH level, anemia and thrombocytopenia were observed. Bone marrow examination revealed 30% atypical large-sized CD19-, CD38+, CD56+ myeloma cells and chromosomal abnormalities. Although the symptoms were improved temporarily after a third course of VMMD therapy, disease aggravation occurred again, and extramedullary masses appeared on the head, face and pelvis. VAD therapy was performed without effect, and the patient died about 2 months after recurrence. This was a comparatively rare case of fulminant multiple myeloma occurring in the terminal stage.
Tanigawa
M
M
Department of Internal Medicine, Yamada Red Cross Hospital.
Tamaki
S
S
Fujieda
A
A
Miyashita
H
H
Tanaka
K
K
Ichioka
M
M
Taniguchi
M
M
Tsuji
K
K
Miyanishi
E
E
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis*; D007146:Immunoglobulin lambda-Chains / Q000032:analysis*; D016898:Interferon-alpha / Q000008:administration & dosage; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology*; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D007070:Immunoglobulin A; D007146:Immunoglobulin lambda-Chains; D016898:Interferon-alpha; D009607:Nitrosourea Compounds; D014750:Vincristine; D003907:Dexamethasone; D008558:Melphalan; C020766:ranimustine